Dengue vaccine safety checked in pregnant women
NCT ID NCT04486638
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tracks 500 pregnant women in the US who received the Dengvaxia dengue vaccine. Researchers will monitor mothers and their babies for any side effects or pregnancy complications. The goal is to gather safety data, not to test the vaccine's effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dengue Tetravalent Vaccine, Live (Dengvaxia)
- What this could lead to
- If this study finds no safety problems, it could provide reassurance about using Dengvaxia during pregnancy.
- What could go wrong
- This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may take years and depend on voluntary reporting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DENGUE VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Investigational Site
RECRUITINGSan Juan, Puerto Rico